β2-adrenergic receptors mediate cardioprotection through crosstalk with mitochondrial cell death pathways

J Mol Cell Cardiol. 2011 Nov;51(5):781-9. doi: 10.1016/j.yjmcc.2011.06.019. Epub 2011 Jul 2.

Abstract

β-adrenergic receptors (β-ARs) modulate cardiotoxicity/cardioprotection through crosstalk with multiple signaling pathways. We have previously shown that β2-ARs are cardioprotective during exposure to oxidative stress induced by doxorubicin (DOX). DOX cardiotoxicity is mediated in part through a Ca(2+)-dependent opening of the mitochondrial permeability transition (MPT), however the signals linking a cell surface receptor like the β2-AR to regulators of mitochondrial function are not clear. The objective of this study was to assess mechanisms of crosstalk between β2-ARs and mitochondrial cell death pathways. DOX administered to WT mice resulted in no acute mortality, however 85% of β2-/- mice died within 30 min. Several pro- and anti-survival pathways were altered. The pro-survival kinase, εPKC, was decreased by 64% in β2-/- after DOX vs WT (p<0.01); the εPKC activator ψεRACK partially rescued these mice (47% reduction in mortality). Activity of the pro-survival kinase Akt decreased by 76% in β2-/- after DOX vs WT (p<0.01). The α1-antagonist prazosin restored Akt activity to normal and also partially reversed the mortality (45%). Deletion of the β2-AR increased rate of Ca(2+) release by 75% and peak [Ca(2+)](i) by 20% respectively in isolated cardiomyocytes; the Ca(2+) channel blocker verapamil also partially rescued the β2-/- (26%). Mitochondrial architecture was disrupted and complex I and II activities decreased by 40.9% and 34.6% respectively after DOX only in β2-/-. The MPT blocker cyclosporine reduced DOX mortality by 41% and prazosin plus cyclosporine acted synergistically to decrease mortality by 85%. β2-ARs activate pro-survival kinases and attenuate mitochondrial dysfunction during oxidative stress; absence of β2-ARs enhances cardiotoxicity via negative regulation of survival kinases and enhancement of intracellular Ca(2+), thus predisposing the mitochondria to opening of the MPT.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Adrenergic alpha-1 Receptor Antagonists / pharmacology
  • Animals
  • Apoptosis / drug effects
  • Calcium / metabolism*
  • Calcium Channel Blockers / pharmacology
  • Cardiomyopathies / drug therapy
  • Cardiomyopathies / genetics
  • Cardiomyopathies / metabolism*
  • Cardiomyopathies / mortality
  • Cardiomyopathies / physiopathology
  • Cyclosporine / pharmacology
  • Doxorubicin / adverse effects*
  • Doxorubicin / antagonists & inhibitors
  • Enzyme Inhibitors / pharmacology
  • Male
  • Mice
  • Mice, Knockout
  • Mitochondria / drug effects
  • Mitochondria / genetics
  • Mitochondria / metabolism*
  • Mitochondrial Membrane Transport Proteins / antagonists & inhibitors
  • Mitochondrial Membrane Transport Proteins / metabolism*
  • Mitochondrial Permeability Transition Pore
  • Myocytes, Cardiac / cytology
  • Myocytes, Cardiac / drug effects
  • Myocytes, Cardiac / metabolism*
  • Oxidative Stress / drug effects
  • Oxidative Stress / genetics
  • Prazosin / pharmacology
  • Proto-Oncogene Proteins c-akt / genetics
  • Proto-Oncogene Proteins c-akt / metabolism
  • Receptors, Adrenergic, beta-2 / metabolism*
  • Signal Transduction* / drug effects
  • Signal Transduction* / genetics
  • Survival Rate
  • Verapamil / pharmacology

Substances

  • Adrenergic alpha-1 Receptor Antagonists
  • Calcium Channel Blockers
  • Enzyme Inhibitors
  • Mitochondrial Membrane Transport Proteins
  • Mitochondrial Permeability Transition Pore
  • Receptors, Adrenergic, beta-2
  • Doxorubicin
  • Cyclosporine
  • Verapamil
  • Proto-Oncogene Proteins c-akt
  • Calcium
  • Prazosin